Case Report
Recurrent pelvic stromal tumor with colon fistula of left leg: a case report

Jing Luo, Hongliang Yao, Sanlin Lei, Yong Xie

Department of Gastrointestinal Surgery, Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China

Received March 8, 2017; Accepted September 4, 2017; Epub October 15, 2017; Published October 30, 2017

Abstract: The oral tyrosine kinase inhibitor (TKI), sunitinib malate, has been widely used in patients with gastrointestinal stromal tumors (GISTs). The formation of colon fistula of left leg during treatment with sunitinib for recurrent pelvic stromal tumor has not been described before. We describe a 47 years old man who had received several surgical resections and taken imatinib mesylate due to recurrent gastrointestinal stromal tumors. Recently, in consideration of imatinib resistance, the patient changed the drug from imatinib to sunitinib. Unfortunately, a fistula developed between the sigmoid colon cavity and the left leg skin. Thus, the patient received surgery under general anesthesia after active nutrition support therapy and the vacuum assisted closure therapy was taken to promote wound healing and avoid skin grafting or reduce the grafting area. Finally, the patient was discharged with a better health condition without skin grafting. This is the first description of recurrent pelvic stromal tumor with colon fistula of left leg under sunitinib treatment. From this case, clinicians should raise awareness of the possibility of intestinal perforation and enterocutaneous fistula for patients with gastrointestinal stromal tumors, especially when the intestine is involved by tumor and under the treatment of molecular targeted drugs.

Keywords: Gastrointestinal stromal tumors, colon fistula of left leg, sunitinib, case report, vacuum-assisted closure

Background

GISTs remain the most common mesenchymal neoplasm of gastrointestinal tract, accounting for 0.1-3% of gastrointestinal tumors [1, 2]. GISTs are considered to be a tumor caused by c-Kit or PDGFRα mutations, and were solid tumors that need TKI therapy [3]. Imatinib mesylate, a small molecule TKI, has been proven to be beneficial to patients with Kit-positive GISTs that failed to resection or with metastatic lesions by prolonging PFS, RFS and OS. Present, imatinib has been regarded as the first-line drug for GISTs [4-7].

Sunitinib malate, another novel oral small-molecule TKI, has anti-tumor and anti-angiogenesis functions through interacting with angiogenesis receptors, including platelet-derived growth factor receptors and the VEGF receptors [8, 9]. For GISTs patients who are resistant or intolerant to imatinib, sunitinib could be deemed as the second-line drug. A randomized controlled trial reported that sunitinib could apparently slow tumor progression and is generally well tolerated, with most side-effects being mild to moderate [10]. The most common side effects included fatigue (34%), diarrhea (24%), skin discoloration (25%), nausea (24%) and anorexia (19%). Previous studies confirmed fistula formation was rare in GISTs [8, 10, 11]. However, recently, some case reports demonstrated vesicocutaneous fistula, tumor fistula and enterocutaneous fistula formation in GISTs patients treated with sunitinib [12-14]. This study reported the clinical aspects of a rare enterocutaneous fistula between enteric cavity and the left leg skin in a GISTs patient with repeated recurrence and surgeries, since the case was easy to be misdiagnosed for atypical clinical manifestation.

Case presentation

A 47-year-old man, the Han nationality, was admitted to our hospital for the fourth time due to recurrent abdominal pain for 19 years, and accompanied by the left leg pain for 5 days on
Recurrent pelvic stromal tumor with colon fistula of left leg: a case report

28th September, 2014. In 1995, the patient was firstly admitted to our hospital due to abdominal pain. The contrast-enhanced CT of pelvic cavity and the barium enema revealed a mass in the rectovesical pouch (7.5 cm×10 cm×13 cm). After huge mass resection in pelvic peritoneum and jejunum part resection and anastomosis, biopsy result revealed the existence of low-grade malignant leiomyosarcoma of small intestinal (Now it confirmed to be GISTs). The patient was discharged with a better health condition.

The patient had no special discomfort until June 2008, and was admitted to our hospital again for abdominal pain. Pelvic CT showed an occupied lesion (8.5 cm×7.5 cm) with hemorrhage and necrosis, the source and property were unknown. Finally, the pathological diagnosis confirmed GISTs with medium risk after the pelvic mass resection. The mitotic index was 2/50 HPF and the result of immunohistochemical examination was CD117(+), NSE(+), Vim(+), CD34(+), Actin(+), CD68(-) and S100(-). The patient received adjuvant therapy with imatinib

Figure 1. Abdominal CT showed GISTs recurrence on July 17th 2014.

Figure 2. CT reexamination showed recurrent GISTs on August 18th 2014.
Recurrent pelvic stromal tumor with colon fistula of left leg: a case report

With the consideration of GISTs recurrence, he received recurrent stromal tumor resection, during which a mass about 2 cm in diameter in the left colon ditch was found adhesion to omentum and an irregular and fragile mass was occupied in the left of the upper rectum, both of which were removed, and the wound was dipped in dehydrated alcohol to inactivate the tumor cells. The gene test after surgery showed KIT E11 mutation and KIT E9, E13, E17 and PDGFα E12, E18 without mutation. Therefore, the patient was treated with imatinib (400 mg/d) continually for adjuvant therapy. In January 2013, pelvic CT showed no abnormal lesion. However, the patient felt abdominal pain on July 17th 2014 and abdominal CT showed GISTs recurrence (Figure 1). Considering imatinib resistance, sunitinib (37.5 mg per day) was administrated for relieving dis-
comfort. New symptoms appeared, including mild diarrhea, anorexia and insomnia. CT reexamination on August 18th 2014 showed recurrent GISTs (Figure 2). On September 22, with the abdominal pain worsen, and considering that sunitinib was invalid, the patient returned to imatinib (600 mg per day), and added to 800 mg per day in 4 days. On September 24, symptom of pain in the inner left leg appeared, which was persistently swollen without wandering pain. The patient was admitted to our hospital for the fourth time.

For previous medical history, in 2011, he underwent thyroid papillary carcinoma resection without recurrence until now. The family history was unremarkable. Physical examination showed a 16 cm old surgery scar in lower abdomen and the left leg was swelling with high temperature and ecchymosis distributed, without blisters. Other physical examination was normal. During hospitalization, the vascular ultrasound and venography of the left leg were both normal, and abdominal CT showed that the mass in left lower abdomen was smaller with 77 mm×64 mm and density was lower (Figure 3).

The patient withdrew imatinib on October 6 (Table 1). The more and more swollen leg resulted in blisters, then blisters bursted, followed by fecal effusion flowing out, almost 500 ml per day when using negative pressure suc-
Recurrent pelvic stromal tumor with colon fistula of left leg: a case report

Effusion bacterial culture showed a wide range of drug-resistant Escherichia coli and the effective antibiotics were used. CT of the pelvic and the left leg on October 24th, 2014 showed smaller mass in the left pelvic (64 mm×63 mm), and incomplete lower part of descending colon and connected enteric cavity with air of low abdominal wall, intestinal fistula was suspected; the left thigh became gangrenous and enlarged lymph nodes in the left groin (Figure 5). The barium examination (Figure 6) of the whole digestive tract showed decreased gastrointestinal motility and soft tissue emphysema of the left thigh. Barium enema showed that the distal part of descending colon was connected with the soft tissue of the left thigh, conforming to the diagnosis of intestinal fistula; subcutaneous emphysema of the left thigh. According to the examinations above, the diagnosis of intestinocutaneous fistula was confirmed. And at this moment, the patient still had amounts of fecal effusion, and significantly swollen left thigh and the whole left leg, with red skin and high temperature, and many burs-}

Figure 7. Fistula and the sinus tracts. The coarse arrow showed the fistula and the thin arrow showed the intestinal contents corrosion formation from the sinus tracts.

Figure 8. VAC for the left leg after operation.
Recurrent pelvic stromal tumor with colon fistula of left leg: a case report

Immunohistochemistry: CD117(+), CD34(focal +), Dog-1(+), SMA(weak+), S100(-); (the left leg): one piece of bean-size tissue. Microscopically, many inflammatory exudation, necrosis material and proliferative granulation tissue can be seen, without mucous membrane covered, and there are many neutrophils infiltrated in mesenchyme, all of which conforms with purulent inflammation, without tumors (GISTs) invasion. The gene test showed KIT E11 mutation and KIT E9, E13, E17, PDGFα E12 and E18 without mutation. After discharged in January 2015, the patient did the CT reexamination every month, none of which had a relapse performance. The last follow up was performed in November 2016, the patient is survived now and can walk by himself.

Discussion

The patient in our report had received three recurrent lesions resections since diagnosed with low-grade malignant leiomyosarcoma of small intestinal in 1995 and received imatinib for adjuvant therapy for diagnosed GISTs in 2008. The Expert Consensus on Diagnosis and Therapy of GISTs suggested that for patients diagnosed with limitedly recurrent or metastatic GISTs, if the molecular targeted drugs are effective and only one or several lesions progress, tumor cytoreduction can be chosen by removing progressive or metastatic lesions as many as possible [15]. Therefore, for these patients with repeatedly recurrent or metastatic GISTs, if the molecular targeted drugs are useful and the baseline performance status are well, tumor cytoreduction can be chosen for removing lesions and prolonging RFS and OS.

Pain and swollen in the left leg was one of the main symptoms of this patient. In consideration of the tumor history for many years, clinicians may tend to diagnose the patient with vascular embolization, especially the cancer embolus, which has been confirmed wrongly by the following examinations, and intestinocutaneous fistula was the correct diagnosis. Intestinocutaneous fistula did not occur during the administration of imatinib, then after several repeated recurrences, imatinib treatment was replaced with sunitinib (37.5 mg/d) in consideration of imatinib resistance. Although the abdominal pain relieved gradually, the abdominal pain aggravated suddenly 2 months later, accompanied with a new symptom of pain in the left leg, which made us choose the imatinib (800 mg/d) treatment. Previous studies have confirmed that sunitinib has the effect of anti-angiogenesis, and has the ability to decrease the numbers of blood vessels and blood flow in the center of tumor to shrink tumor and promote tumor cells necrosis through inhibiting VEGF-VEGFR pathway [8]. However, the anti-angiogenesis effects may significantly affects injured mucosal homeostasis and wound healing. In March 2012, when the patient had the third surgery, tumors in the left colon ditch and in the left of the upper rectum were resected, and the wound was dipped in dehydrated alcohol to inactivate tumor cells. And the anti-angiogenesis effects of sunitinib caused intestinal perforation, which led to the concentration of intestinal contents in the left iliaca fossa. And through the left femoral canal, the intestinal contents flowed into the left leg, resulting in pain and swollen. The more the drainage was, the more the pressure in the left leg was, and finally, blisters appeared and ruptured. Many previous studies showed that patients tolerate sunitinib well and fistula formation hardly occurs. However, a literature in 2006 has reported a case report about gastric-intestinal perforation happened in patients with GISTs when using sunitinib at a high dose of more than 75 mg per day [16]. In our case, the enterocutaneous fistula occurred when the patient using sunitinib for 2 months, and the intestinal content leakage was localized to the intestinal wall that adhered to GISTs, and flowed to the left inner thigh which is far away from the primary lesion through the physical channel-femoral canal, leading the left thigh to gangrene.

The patient received infected wound debridement for many times due to sever necrotizing fasciitis of left leg, and soft tissue and skin were seriously damaged. Besides, in order to promote wound healing and avoid skin graft, we determined to use VAC, also called NPWT. Fleischmann, et al reported that VAC was effectively used in treating damaged soft tissue of open fractures for the first time, followed by lectures about effective treatment of VAC in dissected wounds of skin and fascia and acute and chronic infected wounds by the same investigators [17-20]. VAC promotes wounds healing through macroscopic and microscopic pathways. Macroscopically, vacuum aspiration can promote concentration of wound edges and helps to discharge infections and necrotic.
Recurrent pelvic stromal tumor with colon fistula of left leg: a case report

In conclusion, this is the first description of recurrent pelvic stromal tumor with colon fistula of left leg under sunitinib treatment. The antiangiogenesis effect of the drug may partially related to the intestinal perforation and fistula formation. Therefore, for patients with GISTs involved in gastrointestinal tract or had residual tumor cells after resection, and receiving molecular targeted drugs, especially sunitinib, clinicians should take the possibility of intestinal perforation or enterocutaneous fistula formation into consideration.

Disclosure of conflict of interest

None.

Abbreviations

GISTs, gastrointestinal stromal tumors; CT, computer tomography; EUS, endoscopic ultrasonography; NPWT, negative pressure wound therapy; RFS, recurrent-free-survival; OS, overall survival; PFS, progression free survival; TKI, tyrosine kinase inhibitors; VAC, vacuum-assisted closure; VEGF, vascular endothelial growth factor; PET-CT, positron emission tomography-computed tomography.

Address correspondence to: Hongliang Yao, Department of Gastrointestinal Surgery, Second Xiangya Hospital, Central South University, Renmin Road, Changsha 410011, Hunan, China. Tel: 1380845-2603; E-mail: yaohl0326@csu.edu.cn

References

Recurrent pelvic stromal tumor with colon fistula of left leg: a case report


